FLEXBUMIN 5% and 25% are indicated for hypovolemia, hypoalbuminemia (burns), and cardiopulmonary bypass surgery. Albumin is not indicated as an intravenous nutrient.
 FLEXBUMIN 25% is also indicated for hypoalbuminemia due to Adult Respiratory Distress Syndrome (ARDS) and nephrosis, and for hemolytic disease of the newborn (HDN).

Flexbumin bag

Trusted by
Hospitals for
More Than
15 Years.

FLEXBUMIN is the first human albumin in
a flexible, shatterproof container.1-3*

* FLEXBUMIN 25% Solution was FDA approved on
October 11, 2005.

Flexbumin bag
Icon

Request a demo bag Icon

Discover why hospitals have trusted FLEXBUMIN in the GALAXY® container for more than 15 years.
Icon

Request a visit Icon

Find out how FLEXBUMIN 25% and 5% in the GALAXY container can help deliver proven sterility, product safety, and efficiency in your institution.

Proven Sterility Without an Overwrap.

Delivered with no extra packaging, FLEXBUMIN in the GALAXY container is designed to maintain sterility during setup and administration.1-5

Learn More

Designed With Safety in Mind.

Delivered in a shatterproof, flexible container, FLEXBUMIN helps reduce risk in critical situations.1-8

Learn More

Designed With Efficiency in Mind.

Lightweight and flexible, the FLEXBUMIN container helps enhance storage and setup efficiencies.1-3,9-10

Learn More

Designed With Environmental Sustainability in Mind.

Delivered in a lightweight, flexible container, FLEXBUMIN helps reduce environmental impacts throughout the product lifecycle.1-3,10-12†

Learn More

†Calculations based on BUMINATE® [Albumin (Human)], USP, 5% and 25% Solutions in glass bottles of equal volume.

References

  1. FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution [prescribing information]. Lexington, MA: Baxalta.
  2. FLEXBUMIN 5% [Albumin (Human)], USP, 5% Solution [prescribing information]. Lexington, MA: Baxalta.
  3. Data on file. VV-MED-7455—FLEX-013 FLEXBUMIN biologics license application.
  4. Maki DG, Rosenthal VD, Salomao R, Franzetti F, Rangel-Frausto MS. Impact of switching from an open to a closed infusion system on rates of central line-associated bloodstream infection: a meta-analysis of time-sequence cohort studies in 4 countries. Infect Control Hosp Epidemiol. 2011;32(1):50-58.
  5. The Joint Commission. Preventing Central Line-Associated Bloodstream Infections: A Global Challenge, A Global Perspective. https://www.jointcommission.org/-/media/tjc/documents/resources/hai/clabsi_monographpdf.pdf. Accessed September 17, 2020.
  6. Kruer RM, Jarrell AS, Latif A. Reducing medication errors in critical care: a multimodal approach. Clin Pharmacol. 2014;6:117-126.
  7. van der Sluijs AF, van Slobbe-Bijlsma ER, Goossens A, Vlaar AP, Dongelmans DA. Reducing errors in the administration of medication with infusion pumps in the intensive care department: A lean approach. SAGE Open Med. 2019;7:2050312118822629.
  8. U.S. Food and Drug Administration. Safety Considerations for Product Design to Minimize Medication Errors. Guidance for Industry. https://www.fda.gov/files/drugs/published/Safety-Considerations-for-Product-Design-to-Minimize-Medication-Errors-Guidance-for-Industry.pdf. Published April 2016. Accessed September 17, 2020.
  9. Data on file VV-MED-7220—FLEX-006 Plastic vs. glass weights and dimensions.
  10. Data on file. GALAXY storage space comparisons.
  11. Data on file (No. 68128FR). GALAXY 250 mL weight comparisons. June 20, 2012.
  12. Deloitte Consulting. Final results for albumin packaged as FLEXBUMIN and BUMINATE. October 2012.

Indications and Limitation of Use

FLEXBUMIN [Albumin (Human)] 5% and 25% are indicated for hypovolemia, hypoalbuminemia (burns), and cardiopulmonary bypass surgery. Albumin is not indicated as an intravenous nutrient.
 FLEXBUMIN 25% is also indicated for hypoalbuminemia due to Adult Respiratory Distress Syndrome (ARDS) and nephrosis, and for hemolytic disease of the newborn (HDN).

Expand+

Important Safety Information

Contraindications

  • History of hypersensitivity reaction to albumin preparations or to any of the excipients (N-acetyltryptophan and sodium caprylate). Reactions have included anaphylactic shock, anaphylactic
 reaction, or hypersensitivity/allergic reactions.
  • 
Severe anemia or cardiac failure with normal or increased intravascular volume.

Warnings and Precautions

Hypersensitivity Reactions: Have been observed (including anaphylactic reactions). If hypersensitivity reaction is suspected, discontinue administration immediately and implement appropriate standard medical treatment.

Hypervolemia/Hemodilution: Under conditions where hypervolemia and/or hemodilution may occur, adjust the dose and rate of infusion to the patient’s volume status. When administering large volumes, monitor hemodynamic parameters. Ensure adequate substitution of other blood constituents and monitor electrolyte balance. Discontinue administration at the first clinical signs of cardiovascular overload.

Hemodynamics: Closely monitor hemodynamic parameters after administration for evidence of cardiac or respiratory failure, renal failure, or increasing intracranial pressure.

Blood Pressure: Monitor blood pressure in trauma patients and postoperative surgery patients in order to detect re-bleeding secondary to clot disruption.

Hemolysis: Do not dilute with Sterile Water for Injection, as there is potential risk of fatal hemolysis and acute renal failure in recipients.

Transmission of Infectious Agents: Because FLEXBUMIN 5% and 25% are made from human plasma, they may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No cases of transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) or variant Creutzfeldt-Jakob disease (vCJD) have ever been identified.

Adverse Reactions

The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema.

Administration Caution

Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please click for Full Prescribing Information for FLEXBUMIN 5% and FLEXBUMIN 25%.